Goldman Sachs upgrades Ionis Pharmaceuticals stock to Neutral on pipeline potential
PositiveFinancial Markets

Goldman Sachs has upgraded Ionis Pharmaceuticals' stock to a Neutral rating, highlighting the company's promising pipeline potential. This upgrade is significant as it reflects confidence in Ionis' ability to develop innovative therapies, which could lead to increased investor interest and potentially higher stock performance in the future.
— Curated by the World Pulse Now AI Editorial System